Page last updated: 2024-12-07

cgp 52432

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID132252
CHEMBL ID1449133
CHEBI ID91493
SCHEMBL ID367081
MeSH IDM0220996

Synonyms (41)

Synonym
139667-74-6
(3-(((3,4-dichlorophenyl)methyl)amino)propyl)(diethoxymethyl) phosphinic acid
phosphinic acid, (3-(((3,4-dichlorophenyl)methyl)amino)propyl)(diethoxymethyl)-
4zh667rfw5 ,
unii-4zh667rfw5
cgp-52432
BRD-A04668240-001-01-5
tocris-1246
NCGC00025075-01
BIOMOL-NT_000239
BPBIO1_000596
NCGC00025075-02
cgp 52432 ,
3-[(3,4-dichlorophenyl)methylamino]propyl-(diethoxymethyl)phosphinic acid
SCHEMBL367081
3-[[(3,4-dichlorophenyl)methyl]amino]propyl] diethoxymethyl)phosphinic acid
CHEMBL1449133
AKOS024456486
DTXSID20161147
SR-01000597422-3
sr-01000597422
CHEBI:91493
[3-[[(3,4-dichlorphenyl)methyl]amino]propyl](diethoxymethyl)phosphinic acid
J-007303
cgp52432
HY-103531
CS-0028031
(3-((3,4-dichlorobenzyl)amino)propyl)(diethoxymethyl)phosphinic acid
BCP29115
Q27163330
cgp-52432,
cgp 52432,
D80638
phosphinic acid, p-[3-[[(3,4-dichlorophenyl)methyl]amino]propyl]-p-(diethoxymethyl)-
EX-A4241
3-[[(3,4-dichlorophenyl)methyl]amino]propyl]diethoxymethyl)phosphinic acid
c15h24cl2no4p
HB0958
3-[(3,4-dichlorobenzyl)amino]propyl(diethoxymethyl)phosphinic acid
p-[3-[[(3,4-dichlorophenyl)methyl]amino]propyl]-p-(diethoxymethyl)phosphinic acid
[3-[[(3,4-dichlorophenyl)methyl]amino]propyl](diethoxymethyl)-phosphinic acid

Research Excerpts

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
dichlorobenzeneAny member of the class of chlorobenzenes carrying two chloro groups at unspecified positions.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
15-lipoxygenase, partialHomo sapiens (human)Potency10.00000.012610.691788.5700AID887
TDP1 proteinHomo sapiens (human)Potency0.26610.000811.382244.6684AID686978
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (71)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's9 (12.68)18.2507
2000's28 (39.44)29.6817
2010's31 (43.66)24.3611
2020's3 (4.23)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 18.11

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index18.11 (24.57)
Research Supply Index4.29 (2.92)
Research Growth Index4.77 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (18.11)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (1.39%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other71 (98.61%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]